FR20C1048I1 - Utilisation du désoxycholate de sodium pour l' élimination non chirurgicale de graisse - Google Patents

Utilisation du désoxycholate de sodium pour l' élimination non chirurgicale de graisse

Info

Publication number
FR20C1048I1
FR20C1048I1 FR20C1048C FR20C1048C FR20C1048I1 FR 20C1048 I1 FR20C1048 I1 FR 20C1048I1 FR 20C1048 C FR20C1048 C FR 20C1048C FR 20C1048 C FR20C1048 C FR 20C1048C FR 20C1048 I1 FR20C1048 I1 FR 20C1048I1
Authority
FR
France
Prior art keywords
pharmacologically active
fat
sodium deoxycholate
fat removal
dispersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR20C1048C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lundquist Inst For Biomedical Innovation At Harbor Ucla Medical Center
University of California
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
Original Assignee
Lundquist Inst For Biomedical Innovation At Harbor Ucla Medical Center
University of California
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34961536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1048(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundquist Inst For Biomedical Innovation At Harbor Ucla Medical Center, University of California, Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center filed Critical Lundquist Inst For Biomedical Innovation At Harbor Ucla Medical Center
Publication of FR20C1048I1 publication Critical patent/FR20C1048I1/fr
Application granted granted Critical
Publication of FR20C1048I2 publication Critical patent/FR20C1048I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Medicinal Preparation (AREA)
  • Edible Oils And Fats (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
FR20C1048C 2004-05-19 2020-10-07 Utilisation du désoxycholate de sodium pour l' élimination non chirurgicale de graisse Active FR20C1048I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57287904P 2004-05-19 2004-05-19
PCT/US2005/017957 WO2005112942A1 (fr) 2004-05-19 2005-05-19 Procedes et compositions associes pour la reduction de graisse
EP05751896A EP1748780B1 (fr) 2004-05-19 2005-05-19 Procedes et compositions associes pour la reduction de graisse

Publications (2)

Publication Number Publication Date
FR20C1048I1 true FR20C1048I1 (fr) 2020-11-27
FR20C1048I2 FR20C1048I2 (fr) 2024-03-08

Family

ID=34961536

Family Applications (2)

Application Number Title Priority Date Filing Date
FR20C1048C Active FR20C1048I2 (fr) 2004-05-19 2020-10-07 Utilisation du désoxycholate de sodium pour l' élimination non chirurgicale de graisse
FR23C1018C Active FR23C1018I1 (fr) 2004-05-19 2023-04-28 Désoxycholate pour la réduction de graisses

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR23C1018C Active FR23C1018I1 (fr) 2004-05-19 2023-04-28 Désoxycholate pour la réduction de graisses

Country Status (25)

Country Link
US (3) US7622130B2 (fr)
EP (8) EP3424508B1 (fr)
JP (2) JP5060295B2 (fr)
KR (1) KR101217497B1 (fr)
CN (2) CN105233287A (fr)
AT (2) ATE521355T1 (fr)
AU (1) AU2005245002B8 (fr)
CA (1) CA2567298C (fr)
CY (4) CY1111974T1 (fr)
DK (5) DK2422789T3 (fr)
ES (5) ES2372499T3 (fr)
FI (1) FI3692995T3 (fr)
FR (2) FR20C1048I2 (fr)
HK (2) HK1099521A1 (fr)
HU (5) HUE038247T2 (fr)
IL (2) IL179008A (fr)
LT (3) LT2422789T (fr)
MX (1) MXPA06013437A (fr)
NL (1) NL301229I2 (fr)
NZ (2) NZ551000A (fr)
PL (4) PL2422789T3 (fr)
PT (5) PT2422789T (fr)
SI (4) SI2422789T1 (fr)
TR (1) TR201802446T4 (fr)
WO (2) WO2005117900A1 (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
DK2422789T3 (en) 2004-05-19 2018-02-26 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct INJECTABLE COMPOSITION CONTAINING SODIUM DEOXYCHOLATE
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US20060074057A1 (en) * 2004-10-04 2006-04-06 Eric Marchewitz Use of chenodeoxycholic acid for reducing adipose tissue
JP4646669B2 (ja) * 2005-03-30 2011-03-09 キヤノン株式会社 吐出用液体、吐出方法、液滴化方法、カートリッジ及び吐出装置
US20060222695A1 (en) * 2005-04-01 2006-10-05 Filiberto Zadini Deoxycholic acid liposome-based dermatological topical preparation
US20070071706A1 (en) * 2005-09-28 2007-03-29 Filiberto Zadini Lipodissolving dermatological topical preparation
US20090035348A1 (en) * 2005-11-22 2009-02-05 Z & Z Medical Holdings, Inc. Dissolution of arterial plaque
US7676604B2 (en) * 2005-11-22 2010-03-09 Intel Corporation Task context direct indexing in a protocol engine
US8304383B2 (en) 2005-11-22 2012-11-06 Atheronova Operations, Inc. Dissolution of arterial plaque
US20110082124A1 (en) * 2006-02-23 2011-04-07 Kythera Biopharmaceuticals, Inc. Detergent compositions for treatment of lipomas and other conditions
US20090233885A1 (en) * 2006-07-14 2009-09-17 Duncan Diane I Compositions and Methods for Fat Reduction
WO2008066775A2 (fr) * 2006-11-22 2008-06-05 Duncan Diane I Compositions et procédés visant à réduire la graisse et à rétracter la peau
DE102007015701A1 (de) * 2007-03-19 2008-09-25 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue pharmazeutische Zusammensetzungen für die Lipolyse und Verfahren zu deren Herstellung
US8057381B2 (en) * 2007-04-16 2011-11-15 Allen Iii William F Method and implant material for treatment of urinary incontinence
JOP20180077A1 (ar) 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc تركيبات وطرق لحمض صفراوي تخليقي
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
CN106083969B (zh) * 2007-06-19 2018-02-27 凯瑟拉生物制药有限公司 合成胆汁酸组合物、方法和制剂
US7943187B2 (en) 2008-05-23 2011-05-17 Bakr Rabie Paeoniflorin preparations and uses thereof for fat reduction
FR2937554B1 (fr) * 2008-10-27 2010-11-12 Yves Crassas Solutions salines aqueuses pour la destruction de tissus graisseux
US10213441B2 (en) 2009-03-02 2019-02-26 Doris Hexsel Medicinal cosmetic lipoatrophy
JP6006940B2 (ja) * 2009-03-02 2016-10-12 ヘクセル，ドリス 医学的美容脂肪萎縮方法
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
EP2485738A4 (fr) * 2009-10-09 2015-04-01 Atheronova Operations Inc Compositions et procédés destinés à traiter l'obésité
GB2480632A (en) 2010-05-25 2011-11-30 Kythera Biopharmaceuticals Inc Preparation of 12-keto and 12-alpha-hydroxy steroids
BR112013003216A2 (pt) 2010-08-12 2016-05-17 Kythera Biopharmaceuticals Inc composições sintéticas de ácido biliar e métodos
EP2675460A4 (fr) 2011-02-18 2014-07-09 Kythera Biopharmaceuticals Inc Traitement de graisse sous-mentale
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
EP2721047B1 (fr) 2011-06-16 2016-11-16 Kythera Biopharmaceuticals, Inc. Procédés de synthèse et de purification de l'acide désoxycholique
CN108619089A (zh) * 2011-08-23 2018-10-09 凯瑟拉生物制药有限公司 脱氧胆酸和其盐的制剂
EA034320B1 (ru) * 2011-08-23 2020-01-28 Китера Биофармасьютикалз, Инк. Композиции дезоксихолата натрия
PT3305298T (pt) 2011-08-23 2019-07-29 Allergan Sales Llc Formulação do ácido desoxicólico e seus sais
ES2953560T3 (es) * 2011-10-21 2023-11-14 Endo Global Ventures Procedimiento para el tratamiento o reducción de paniculopatía fibrosclerótica edematosa
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
EP2793813A1 (fr) 2011-12-21 2014-10-29 Motolese, Pasquale Composition cosmétique et ses utilisations dans le traitement de lipodystrophies
NZ766918A (en) 2012-01-12 2023-03-31 Auxilium Int Holdings Inc Clostridium histolyticum enzymes and methods for the use thereof
MX2015006390A (es) 2012-11-21 2015-08-05 Topokine Therapeutics Inc Metodos y composiciones para incrementar localmente la grasa corporal.
NO2753788T3 (fr) 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
WO2015179282A1 (fr) 2014-05-20 2015-11-26 Topokine Therapeutics, Inc. Compositions topiques comprenant une thiazolidinedione
AU2015270099A1 (en) * 2014-06-01 2016-12-15 Galmed Research And Development Ltd. Fatty acid bile acid conjugates for treatment of lipodystrophy
WO2015200425A1 (fr) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Forme posologique à usage topique
US10729700B2 (en) 2014-06-27 2020-08-04 Medytox Inc. Methods and compositions of bile acids and salts for reduction of fat
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
EP4349414A2 (fr) 2014-12-23 2024-04-10 Dyve Biosciences, Inc. Méthodes et formulations pour l'administration transdermique
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
EP3355882A1 (fr) * 2015-10-01 2018-08-08 Kythera Biopharmaceuticals, Inc. Compositions comprenant une statine pour une utilisation dans des procédés d'adipolyse
WO2017079700A1 (fr) * 2015-11-04 2017-05-11 Kythera Biopharmaceuticals, Inc. Traitements de graisses accumulées à l'aide d'acide désoxycholique et de sels associés
JP6219430B2 (ja) * 2016-03-18 2017-10-25 キテラ バイオファーマシューティカルズ，インコーポレイテッド デオキシコール酸およびその塩類の製剤
ES2905546T3 (es) 2016-06-06 2022-04-11 Crystal Pharma Sau Métodos para la preparación de ácido desoxicólico e intermedios útiles en la preparación de ácido desoxicólico
KR101841193B1 (ko) * 2016-09-22 2018-03-22 이경락 저장성 지방 분해 조성물 및 그의 제조 방법
US20180078621A1 (en) * 2016-09-22 2018-03-22 Kyoung Lack Lee Composition for hypotonic lipolysis and manufacturing method thereof
US11123280B2 (en) 2017-03-01 2021-09-21 Endo Ventures Limited Method of assessing and treating cellulite
US11473074B2 (en) 2017-03-28 2022-10-18 Endo Global Aesthetics Limited Method of producing collagenase
IL266873B2 (en) * 2017-04-21 2024-04-01 Ami Pharm Co Ltd An injectable preparation for local fat reduction without pain, edema and side effects, and a method for its preparation
KR102093872B1 (ko) * 2017-07-03 2020-03-27 진호성 지방제거용 주사제 조성물 및 이의 제조방법
KR20200026273A (ko) * 2017-08-03 2020-03-10 (주)메디톡스 담즙산류를 제조하기 위한 방법
JP6356329B2 (ja) * 2017-09-27 2018-07-11 キテラ バイオファーマシューティカルズ，インコーポレイテッド デオキシコール酸およびその塩類の製剤
CN111511755A (zh) 2017-10-24 2020-08-07 比奥尼斯有限责任公司 脱氧胆酸的制备
CN110302082A (zh) * 2018-03-27 2019-10-08 上海同柏生物科技有限公司 用于减少身体脂肪沉积的技术及组合物制剂与应用
JP6594486B2 (ja) * 2018-06-13 2019-10-23 キテラ バイオファーマシューティカルズ，インコーポレイテッド デオキシコール酸およびその塩類の製剤
KR102116238B1 (ko) * 2018-08-28 2020-05-28 이경락 저장성 지방 분해 조성물 및 그의 제조 방법
EP3713551B1 (fr) 2018-10-16 2023-06-07 Polithera, Inc. Compositions à base d'alcool et leurs utilisations
US11439659B2 (en) * 2018-12-03 2022-09-13 The Regents Of The University Of California Methods and compositions to prevent and treat inflammation and allergic reactions
KR102172439B1 (ko) * 2018-12-05 2020-10-30 송미희 지방 분해용 조성물 및 이를 포함하는 주사제 조성물
KR102064864B1 (ko) 2019-02-08 2020-01-10 (주)제테마 국소 주사용 조성물
KR102111346B1 (ko) 2019-08-20 2020-05-22 아영창 침전으로부터 안정한 소듐디옥시콜레이트를 포함하는 수용액상 조성물
WO2023287261A1 (fr) 2021-07-16 2023-01-19 주식회사 스카이테라퓨틱스 Composition cosmétique comprenant des agrégats moléculaires d'acides biliaires ou de sels d'acide biliaire
WO2024007140A1 (fr) * 2022-07-05 2024-01-11 Glonova Pharma Co., Ltd. Composition pour injection comprenant un composé cytolytique dans un gel, une solution formant un gel ou une suspension formant un gel pour la réduction de la graisse

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113882A (en) * 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
IT1202370B (it) 1976-07-12 1989-02-09 Hoffmann La Roche Soluzioni inietabili in cui l'atti vita' emolitica degli agenti di formazione di micelle naturali e' evitata mediante l'aggiunta di lipoidi e relativi prodotti
US4117121A (en) 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. Method of increasing bile flow and decreasing lipid levels
IT8167097A0 (it) 1981-01-26 1981-01-26 Unilever Nv Composizione cosmetica per il trattamento della pelle o dei capelli
US5288498A (en) 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
GB8417895D0 (en) 1984-07-13 1984-08-15 Marples B A Pharmaceutical anti-fungal composition
JPS61158995A (ja) * 1984-12-28 1986-07-18 Takara Shironaga 脂肪肝，胆石，胃粘膜障害発生の予防薬または治療薬
US4866044A (en) * 1985-07-09 1989-09-12 Takeda Chemical Industries, Ltd. Solubilized composition of poorly-soluble pharmaceutical product
IT1213453B (it) 1985-08-02 1989-12-20 Merz & Co Gmbh & Co Composizione farmaceutica.
US5326562A (en) 1986-06-03 1994-07-05 Incyte Pharmaceuticals, Inc. Pharmaceutical dosage unit for treating inflammation comprising protease nexin-I
US4952411A (en) 1987-02-25 1990-08-28 Trustees Of Columbia University In The City Of New York Method of inhibiting the transmission of AIDS virus
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US4994439A (en) 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
IL89530A0 (en) * 1989-03-08 1989-09-10 Jeffrey J Feigenbaum Compositions containing forskolin
GB8909022D0 (en) 1989-04-20 1989-06-07 Cortecs Ltd Pharmaceutical compositions
EP0408174A1 (fr) * 1989-07-12 1991-01-16 Warner-Lambert Company Composition antiseptique contenant des composés de hexahydro-5-pyrimidinamine
US5085864A (en) 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
AU6461090A (en) 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
CA2033725C (fr) 1990-01-24 2001-05-29 Folker Pittrof Compositions pharmaceutiques et cosmetiques
US6120805A (en) 1990-04-06 2000-09-19 Rhone-Poulenc Rorer Sa Microspheres, process for their preparation and their use
JP3032315B2 (ja) * 1991-01-14 2000-04-17 健二 片桐 脂肪肝治療剤
GB9212511D0 (en) 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
US5674855A (en) 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
US5344822A (en) 1992-08-12 1994-09-06 The Rogosin Institute Methods useful in endotoxin prophylaxis and therapy
US6663885B1 (en) 1993-03-15 2003-12-16 A. Natterman & Cie Gmbh Aqueous liposome system and a method for the preparation of such a liposome system
GB9320597D0 (en) 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US5395545A (en) 1993-10-21 1995-03-07 Akzo N.V. Cleaning solution for automated analyzers
MX9704550A (es) 1994-12-22 1997-10-31 Astra Ab Formulaciones de medicamentos en aerosol.
JP2740153B2 (ja) 1995-03-07 1998-04-15 エフ・ホフマン−ラ ロシユ アーゲー 混合ミセル
US5616342A (en) 1995-04-11 1997-04-01 Pdt, Inc. Emulsioin suitable for administering a poorly water-soluble photosensitizing compound and use thereof
US5759445A (en) 1995-05-24 1998-06-02 Matsushita Electric Industrial Co., Ltd. Lipid-dispersed solution and process for producing the same
US20040101569A1 (en) 1996-05-16 2004-05-27 Lorus Therapeutics Inc. Immunomodulating compositions from bile
WO1998002186A1 (fr) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Compose d'inclusion contenant un agoniste selectif de la serotonine a structure indole
US5952392A (en) 1996-09-17 1999-09-14 Avanir Pharmaceuticals Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition
US7351421B2 (en) 1996-11-05 2008-04-01 Hsing-Wen Sung Drug-eluting stent having collagen drug carrier chemically treated with genipin
US6537561B1 (en) 1997-02-27 2003-03-25 Nippon Shinyaku Co., Ltd. Fat emulsion for oral administration
US5891083A (en) 1997-04-22 1999-04-06 Capella; Rafael F. Suction lipolysis
US20020107291A1 (en) 1997-05-26 2002-08-08 Vincenzo De Tommaso Clear, injectable formulation of an anesthetic compound
US6416779B1 (en) 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US6197327B1 (en) 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
ATE291929T1 (de) 1997-06-13 2005-04-15 Univ Nebraska Zusammensetzungen zur abgabe von biologischen wirkstoffen und verfahren zu ihrer herstellung
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US6281175B1 (en) * 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
US6054421A (en) * 1997-09-23 2000-04-25 Scimed Life Systems, Inc. Medical emulsion lubricant
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US7303768B2 (en) 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US6251428B1 (en) 1998-07-24 2001-06-26 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20050158408A1 (en) 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US6417179B1 (en) 1998-10-13 2002-07-09 Craig G. Burkhart Ear wax solution
US6451286B1 (en) 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
US6375975B1 (en) 1998-12-21 2002-04-23 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary application
US6849263B2 (en) 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ES2433678T3 (es) 1999-03-03 2013-12-12 Eli Lilly & Company Formulaciones farmacéuticas de equinocandina que contienen tensioactivos formadores de micelas
US6350432B1 (en) 1999-03-19 2002-02-26 Generex Pharmaceuticals Incorporated Pressurized container having an aerosolized pharmaceutical composition
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6489312B1 (en) * 1999-06-15 2002-12-03 Medimmune Oncology, Inc. Pharmaceutical formulations comprising aminoalkyl phosphorothioates
US6225343B1 (en) 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
CA2406930C (fr) 2000-02-04 2011-02-15 Seo Hong Yoo Preparation de formes posologiques a base de solutions aqueuse claires a partir d'acides biliaires
GB0009773D0 (en) 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
FR2813189B1 (fr) 2000-08-31 2003-02-28 Oreal Creme cosmetique moussante pour le traitement des peaux grasses
EP1317667A1 (fr) * 2000-09-08 2003-06-11 Dow Global Technologies Inc. Chromatographie d'echange d'ions de detection sequentielle
DE60117043T2 (de) 2000-11-22 2006-07-13 Rxkinetix, Inc., Louisville Behandlung von mukositis
JP2004515532A (ja) 2000-12-13 2004-05-27 フェヘール ヤーノシュ 消化障害及び関連する疾患を治療するための医薬組成物
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040022862A1 (en) 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20030072807A1 (en) 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
EP1367970A1 (fr) * 2001-01-24 2003-12-10 Summanus Pharma, Inc. Polymeres alkylaryl polyether alcool pour ameliorer la respiration nasale
SE0100901D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab New composition
WO2002080883A2 (fr) 2001-03-27 2002-10-17 Phares Pharmaceutical Research N.V. Methode et composition permettant de solubiliser un compose biologiquement actif a faible solubilite dans l'eau
WO2002089849A1 (fr) 2001-05-07 2002-11-14 Corium International Compositions et systemes d'administration d'un anesthesique local
CN1813699B (zh) 2001-06-14 2012-04-18 大塚制药株式会社 药物组合物
US20030083286A1 (en) 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US6713470B2 (en) 2002-01-22 2004-03-30 Ml Laboratories Plc Method of treatment
GB0207529D0 (en) * 2002-04-02 2002-05-08 Norbrook Lab Ltd Injectable veterinary composition for small animals
CA2484637A1 (fr) 2002-05-06 2003-11-20 Elan Pharma International Ltd. Formulations de nystatine nanoparticulaires
EP1509209A1 (fr) 2002-05-23 2005-03-02 UMD, Inc. Compositions et methode d'administration de medicaments par voie transmuqueuse et de cryoprotection
PL375874A1 (en) 2002-07-29 2005-12-12 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US20040220283A1 (en) 2002-07-29 2004-11-04 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US20050019404A1 (en) 2003-06-30 2005-01-27 Hsing-Wen Sung Drug-eluting biodegradable stent
US20050163821A1 (en) 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
KR100482269B1 (ko) 2002-10-08 2005-04-14 센츄론(주) 2,6-디이소프로필페놀을 활성성분으로 하는 수용액상의마취용 주사제 및 그 제조방법
US20040171691A1 (en) 2002-10-29 2004-09-02 Transform Pharmaceuticals, Inc. Propofol with cysteine
US20050079228A1 (en) 2003-05-30 2005-04-14 Ashish Jaiswal Clear, stable topical compositions of clarithromycin and processes for their preparation
JP2007503439A (ja) 2003-08-22 2007-02-22 アクティブバイオティクス インコーポレイティッド リファマイシンアナログおよびそれらの使用法
US20050089555A1 (en) 2003-10-24 2005-04-28 Aventis Pharma Deutschland Gmbh Medicinal targeted local lipolysis
DE10349979B4 (de) * 2003-10-24 2006-05-18 Sanofi-Aventis Deutschland Gmbh Medikamentöse gezielte lokale Lipolyse
JP2007515494A (ja) * 2003-12-22 2007-06-14 アベンティス・ファーマスーティカルズ・インコーポレイテツド 注射可能なフォスファチジルコリン調製物
US20050143347A1 (en) 2003-12-22 2005-06-30 Aventis Pharma Deutschland Gmbh Medicinal lipolysis of accumulations of fat
DE10361067A1 (de) 2003-12-22 2005-07-14 Aventis Pharma Deutschland Gmbh Medikamentöse Lipolyse von Fettansammlungen
KR100638041B1 (ko) 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
DK2422789T3 (en) 2004-05-19 2018-02-26 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct INJECTABLE COMPOSITION CONTAINING SODIUM DEOXYCHOLATE
FR2870741B1 (fr) 2004-05-25 2008-03-14 Coletica Sa Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant.
WO2005117832A1 (fr) 2004-06-03 2005-12-15 Bracco Research Sa Ensemble liposomal pour utilisation therapeutique et/ou diagnostique
US20050287199A1 (en) 2004-06-28 2005-12-29 Teresa Ann Denney Therapeutic micro nutrient composition for lipolysis and drug delivery
WO2006007675A1 (fr) * 2004-07-20 2006-01-26 Libbs Farmacêutica Ltda. Acide cholique et/ou ses derives pour la reduction de la graisse localisee dans le corps humain
US20060074057A1 (en) 2004-10-04 2006-04-06 Eric Marchewitz Use of chenodeoxycholic acid for reducing adipose tissue
US20060222695A1 (en) 2005-04-01 2006-10-05 Filiberto Zadini Deoxycholic acid liposome-based dermatological topical preparation

Also Published As

Publication number Publication date
AU2005245002C1 (en) 2011-12-15
ES2372416T3 (es) 2012-01-19
EP2380576A2 (fr) 2011-10-26
PL1748780T3 (pl) 2012-03-30
HUE038247T2 (hu) 2018-10-29
EP2572718A1 (fr) 2013-03-27
FI3692995T3 (fi) 2023-03-02
SI1748780T1 (sl) 2012-02-29
US8298556B2 (en) 2012-10-30
US20050261258A1 (en) 2005-11-24
CN101018553A (zh) 2007-08-15
DK2422789T3 (en) 2018-02-26
JP2012176966A (ja) 2012-09-13
NZ586818A (en) 2012-09-28
EP1748780A1 (fr) 2007-02-07
CN105233287A (zh) 2016-01-13
AU2005245002B8 (en) 2011-12-15
HUE061343T2 (hu) 2023-06-28
ES2372499T3 (es) 2012-01-20
CY1120146T1 (el) 2018-12-12
CY1112204T1 (el) 2015-12-09
PT2422789T (pt) 2018-02-26
KR101217497B1 (ko) 2013-01-03
ATE518565T1 (de) 2011-08-15
PL1758590T3 (pl) 2012-03-30
IL207126A0 (en) 2010-12-30
HUE049990T2 (hu) 2020-11-30
US20100048527A1 (en) 2010-02-25
HK1101062A1 (en) 2007-10-05
HUS2300016I1 (hu) 2023-05-28
PL2422789T3 (pl) 2018-09-28
DK2380576T3 (da) 2020-06-08
PL3692995T3 (pl) 2023-05-22
KR20070024527A (ko) 2007-03-02
PT3692995T (pt) 2023-02-06
LT2380576T (lt) 2020-08-10
MXPA06013437A (es) 2007-03-23
ES2660172T3 (es) 2018-03-21
CA2567298C (fr) 2013-07-09
LT2422789T (lt) 2018-03-12
DK1758590T3 (da) 2011-11-21
SI2380576T1 (sl) 2020-10-30
ATE521355T1 (de) 2011-09-15
US7622130B2 (en) 2009-11-24
HK1099521A1 (en) 2007-08-17
EP1758590B1 (fr) 2011-08-24
IL207126A (en) 2014-02-27
EP1758590A1 (fr) 2007-03-07
PT1758590E (pt) 2011-11-15
EP2380576A3 (fr) 2012-02-22
EP3424508A1 (fr) 2019-01-09
CY2018008I1 (el) 2020-05-29
PT1748780E (pt) 2011-11-10
US20060154906A1 (en) 2006-07-13
EP2380576B1 (fr) 2020-04-08
EP2422789A1 (fr) 2012-02-29
FR23C1018I1 (fr) 2023-06-23
ES2939383T3 (es) 2023-04-21
NZ551000A (en) 2010-10-29
EP1748780B1 (fr) 2011-08-03
CY1111974T1 (el) 2015-11-04
DK3692995T3 (da) 2023-01-30
EP2422789B1 (fr) 2017-11-22
SI1758590T1 (sl) 2012-03-30
KR101217497B9 (ko) 2022-01-11
SI2422789T1 (en) 2018-07-31
DK1748780T3 (da) 2011-11-21
EP3692995A1 (fr) 2020-08-12
AU2005245002B2 (en) 2011-07-07
HUS1700004I1 (hu) 2017-02-28
LTPA2017006I1 (lt) 2017-03-27
CA2567298A1 (fr) 2005-12-01
WO2005117900A1 (fr) 2005-12-15
IL179008A0 (en) 2007-05-15
JP5060295B2 (ja) 2012-10-31
FR20C1048I2 (fr) 2024-03-08
ES2795749T3 (es) 2020-11-24
EP3424508B1 (fr) 2021-05-05
TR201802446T4 (tr) 2018-03-21
IL179008A (en) 2010-12-30
NL301229I2 (nl) 2023-11-23
EP2550968A1 (fr) 2013-01-30
JP2007538104A (ja) 2007-12-27
AU2005245002A1 (en) 2005-12-01
EP3692995B1 (fr) 2022-11-02
PT2380576T (pt) 2020-06-17
CN101018553B (zh) 2015-11-25
WO2005112942A1 (fr) 2005-12-01

Similar Documents

Publication Publication Date Title
FR20C1048I1 (fr) Utilisation du désoxycholate de sodium pour l' élimination non chirurgicale de graisse
SG161202A1 (en) Methods and related compositions for reduction of fat and skin tightening
TW200518753A (en) Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
BR9814923A (pt) Método para tratamento de doença de alzheimer
TW200616608A (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
HUP0400548A2 (hu) Belső szemnyomást csökkentő hatóanyag-kombinációk alkalmazása glaukoma kezelésére szolgáló gyógyszerkészítmények előállítására
EP1074245A3 (fr) Composition avec des sels minéraux pour un traitement thérapeutique
MY144229A (en) Pyridazine derivatives and their use as therapeutic agents
WO2003103614A3 (fr) Procede et compositions pour le traitement de la panniculopathie fibrosclereuse oedemateuse
CN206453858U (zh) 一种颊部软组织保护器
Hashimoto et al. The experimental study on reference domains of demonstrative pronouns from reclining postures.
ND et al. Multidisciplinary approaches to myofascial pain
Benassi et al. Decrease in toxic potential of tensides when used in association: in vitro study on normal human keratinocytes